下丘脑性肥胖患者的临床管理路径
下丘脑性肥胖(HO)由下丘脑物理性破坏导致体重异常增加,鞍上肿瘤尤其是颅咽管瘤是经典病因。HO常因肿瘤治疗和全垂体功能减退管理而被忽视,表现为下丘脑破坏后第一年快速增重,继而因能量消耗降低而摄食不减少的能量失衡导致难治性肥胖。现有药物对HO疗效低于普通肥胖,饮食、药物和减重手术可减轻HO影响,早期识别有助于在明显增重前干预。
要点
- 下丘脑性肥胖由下丘脑物理性破坏引起,颅咽管瘤等鞍上肿瘤是经典病因。
- HO常被肿瘤治疗和全垂体功能减退管理掩盖而初期未被发现。
- HO表现为下丘脑破坏后第一年快速增重,随后因能量消耗降低而摄食不减少导致难治性肥胖。
核心结论
- 下丘脑性肥胖由下丘脑物理性破坏导致体重异常增加,常被肿瘤治疗和全垂体功能减退管理掩盖而初期未被发现。
- HO表现为下丘脑破坏后第一年快速增重,随后因能量消耗降低而摄食不减少的能量失衡导致难治性肥胖。
- 现有药物对HO疗效低于普通肥胖,饮食、药物和减重手术可减轻HO影响,早期识别有助于在明显增重前干预。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 下丘脑性肥胖定义为下丘脑物理性破坏导致的体重异常增加。
- 鞍上肿瘤尤其是颅咽管瘤是HO的经典病因。
- HO常因患者、家庭和医疗团队专注于肿瘤治疗和全垂体功能减退管理而初期未被发现。
- HO特征为下丘脑破坏后第一年快速增重,随后因能量消耗降低而摄食不减少的能量失衡导致难治性肥胖。
- 现有药物对HO的疗效低于普通肥胖。
临床怎么用
- 饮食干预、药物治疗和减重手术可减轻HO的影响,但并非治愈手段。
- 早期识别HO可为在明显增重发生前进行干预提供机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypothalamic obesity (HO) is defined as abnormal weight gain due to physical destruction of the hypothalamus. Suprasellar tumors, most commonly craniopharyngiomas, are a classic cause of HO. HO often goes unnoticed initially as patients, families, and medical teams are focused on oncologic treatments and management of panhypopituitarism. HO is characterized by rapid weight gain in the first year after hypothalamic destruction followed by refractory obesity due to an energy imbalance of decreased energy expenditure without decreased food intake. Currently available pharmacotherapies are less effective in HO than in common obesity. While not a cure, dietary interventions, pharmacotherapy, and bariatric surgery can mitigate the effects of HO. Early recognition of HO is necessary to give an opportunity to intervene before substantial weight gain occurs. Our goal for this article is to review the pathophysiology of HO and to discuss available treatment options and future directions for prevention and treatment.
引用
- Shoemaker AH, Tamaroff J. Approach to the Patient With Hypothalamic Obesity. J Clin Endocrinol Metab. 2023. PMID: 36413492. doi:10.1210/clinem/dgac678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。